Bioxcel therapeutics reports first quarter 2025 financial results and provides business update

Enrollment complete in serenity at-home pivotal phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia topline data expected in second half of 2025 intended to support potential snda submission for label expansion of igalmi ® in the at-home setting new haven, conn., may 12, 2025 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the first quarter of 2025 and announced that its serenity at-home pivotal phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia is fully enrolled.
BTAI Ratings Summary
BTAI Quant Ranking